A scientist works in a laboratory at the Novavax facility in Gaithersburg, Maryland (Jon Cherry/Bloomberg via Getty Images)

No­vavax tem­pers its rev­enue ex­pec­ta­tions as it un­veils PhI­II da­ta for bi­va­lent boost­er

As No­vavax re­ports third quar­ter re­sults, the vac­cine mak­er is tem­per­ing its ex­pec­ta­tions once again on Covid-19 sales.

The com­pa­ny re­port­ed that it net­ted $725 mil­lion in Q3 and ad­min­is­tered around 94 mil­lion dos­es so far, but it has low­ered its fi­nan­cial guid­ance for the year fur­ther to an even $2 bil­lion from an ex­pect­ed $2.3 bil­lion just last quar­ter. The com­pa­ny al­so low­ered its guid­ance from an es­ti­mat­ed $5 bil­lion dur­ing its Q2 re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.